PATENT CLAIM ANALYSIS

Application Number: 16316714
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-09
Patent Classification: ["548", "364100"]

Abstract:
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Claim (Index 28):
The use according to  claim 27  wherein the cancer is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 99.0
- Lexical Diversity: 1.43333
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14977709', '14072563', '14819541', '14339123', '14820611']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7631065974065381
- 35 USC 102 Novelty (BERT): 0.5081420703187123
- Combined Prediction Score: 0.7376101446977555
- Mean Citation Score: 280.301294
- Max Citation Score: 286.54965
- Similarity Product: 214.7143180511356

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test